TY - JOUR
T1 - Glypican-5 is a tumor suppressor in non-small cell lung cancer cells
AU - Guo, Lixia
AU - Wang, Jingyu
AU - Zhang, Ting
AU - Yang, Yanan
N1 - Funding Information:
We thank Dr. Ping Yang for providing the anti-GPC5 antibody as a gift. This work was partly supported by the Mayo Clinic foundation ( CA190272RELIEF ), the Mayo Center for Individualized Medicine biomarker discovery program lung cancer group fund, and the Mayo Clinic Cancer Center Fraternal Order of Eagles Cancer Research Fund . Y.Y. was also partly supported by an NCI R21 award CA184817.
Publisher Copyright:
© 2016 The Authors.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Glypican-5 (GPC5) belongs to the glypican family of proteoglycans that have been implicated in a variety of physiological processes, ranging from cell proliferation to morphogenesis. However, the role of GPC5 in human cancer remains poorly understood. We report that knockdown of GPC5 in bronchial epithelial cells promoted, and forced expression of GPC5 in non-small lung cancer (NSCLC) cells suppressed, the anchorage-independent cell growth. In vivo, expression of GPC5 inhibited xenograft tumor growth of NSCLC cells. Furthermore, we found that GPC5 was expressed predominantly as a membrane protein, and its expression led to diminished phosphorylation of several oncogenic receptor tyrosine kinases, including the ERBB family members ERBB2 and ERBB3, which play critical roles in lung tumorigenesis. Collectively, our results suggest that GPC5 may act as a tumor suppressor, and reagents that activate GPC5 may be useful for treating NSCLC.
AB - Glypican-5 (GPC5) belongs to the glypican family of proteoglycans that have been implicated in a variety of physiological processes, ranging from cell proliferation to morphogenesis. However, the role of GPC5 in human cancer remains poorly understood. We report that knockdown of GPC5 in bronchial epithelial cells promoted, and forced expression of GPC5 in non-small lung cancer (NSCLC) cells suppressed, the anchorage-independent cell growth. In vivo, expression of GPC5 inhibited xenograft tumor growth of NSCLC cells. Furthermore, we found that GPC5 was expressed predominantly as a membrane protein, and its expression led to diminished phosphorylation of several oncogenic receptor tyrosine kinases, including the ERBB family members ERBB2 and ERBB3, which play critical roles in lung tumorigenesis. Collectively, our results suggest that GPC5 may act as a tumor suppressor, and reagents that activate GPC5 may be useful for treating NSCLC.
KW - Cell signaling
KW - Glypican-5
KW - Lung cancer
KW - Tumor suppressor
UR - http://www.scopus.com/inward/record.url?scp=84961730244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961730244&partnerID=8YFLogxK
U2 - 10.1016/j.bbrep.2016.03.010
DO - 10.1016/j.bbrep.2016.03.010
M3 - Article
AN - SCOPUS:84961730244
SN - 2405-5808
VL - 6
SP - 108
EP - 112
JO - Biochemistry and Biophysics Reports
JF - Biochemistry and Biophysics Reports
ER -